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test). However, in a subgroup of patients with eGFR below 
median value (78.6 ml/min/1.73m2) the rs854560 AA 
homozygotes had a significantly lower probability of sur-
vival (p = 0.047, log-rank test). The AA genotype of the 
rs854560 SNPs of the PON1 gene is associated with 
increased mortality in patients after myocardial infarction 
in the subpopulation of patients with lowered eGFR. This 
phenomenon may be explained by potentially lower PON1 
activity in kidney disease.
Keywords Paraoxonase · Myocardial infarction · 
Prognosis · rs662 · rs854560 · Gene polymorphism · Renal 
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Introduction
Paraoxonase 1 (PON1) is an enzyme associated with high 
density lipoprotein (HDL) that is responsible for its antiox-
idant properties. PON1 hydrolyzes oxidized phospholipids 
and cholesterol esters [1]. The activity of PON1 was shown 
to be decreased in patients with coronary artery disease, 
myocardial infarction or chronic kidney disease [2–5]. In 
patients with coronary artery disease decreased PON1 
activity leads to malfunction of the HDL molecule with 
subsequent activation of the LOX-1 receptor (an endothe-
lial lectin-like oxidized LDL-receptor) and endothelial 
PKCβII, followed by inhibition of eNOS-activating path-
ways and decreased NO production [6]. In this way, the 
dysfunctional HDL of impaired function fails to stimulate 
endothelial repair.
The other factors that influence PON1 activity are rs662 
(Q192R) and rs854560 (L55M) single nucleotide poly-
morphisms (SNPs), [7]. The rs662 SNP leads to transition 
between adenine and guanine nucleobases that results in 
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patients depending on their eGFR. The study group com-
prised 634 patients (mean age 62.3 ± 11.85 years; 25.2 % 
of women, n = 160; PCI successful in 92.3 %, n = 585). 
No clinically relevant differences in baseline characteristics 
were found between the genotypes. No association between 
either genotype and 5-year mortality was found: p = 0.4 
for the rs662 SNP, p = 0.73 for the rs854560 one (log-rank 
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glutamine-to-arginine substitution at codon 192 (Q192R). 
In the case of rs854560 SNP thymine to adenine transver-
sion leads to leucine/methionine variability at codon 55 
(L55M). In both cases we receive a missense mutation. The 
rs662 SNP is the only one that leads to Q192R substitution 
and, analogically, only the rs854560 SNP leads to L55M 
variability in a PON1 gene. Therefore rs662 is a synonym 
for Q192R polymorphism and rs854560 is a synonym for 
an L55M one. The 192Q (AA) and 55M (AA) are variants 
associated with lower PON1 activity [7]. This also jus-
tifies combined analysis of T and G allel carriers, vs AA 
homozygotes in both SNPs. The rs662 AA genotype was 
linked with an unfavorable lipid profile [8] and the lowest 
PON1 activity in patients with chronic kidney disease [9].
There are several case–control studies that investigate the 
influence of both SNPs on coronary artery disease preva-
lence. However, a meta-analysis comprising 43 such studies 
showed no significant association [10]. Reports concerning 
the link between the rs662 SNP and myocardial infarction 
are also ambiguous. In the REGICOR study, AA genotype 
was significantly more frequent in patients with myocardial 
infarction compared to control group [3]. In contrast, there 
are reports that the R allele is associated with increased risk 
of an acute coronary syndrome [11, 12]. On the other hand, 
the multicenter ECTIM study revealed no link between 
PON1 polymorphism and myocardial infarction [13].
The link between rs662 and rs854560 SNPs and coro-
nary artery disease remains unclear. In spite of that, it has 
been proved that they influence 10-year cardiovascular 
mortality in this group of patients [1]. The high-risk gen-
otype was the AA in both cases (192Q and 55M). This 
association remained significant after adjustment for lipid 
parameters and smoking status.
We assumed that a comparable trend could be observed 
in long-term observation of patients after myocardial 
infarction. Therefore the aim of our study was to inves-
tigate the association of rs662 and rs854560 SNPs of the 
PON1 gene with 5-year overall mortality in patients with 
ST-elevation myocardial infarction (STEMI).
Materials and methods
Material
The study group comprised consecutive patients with 
STEMI who were hospitalized in the years 2001–2005 
and survived their first 48 h after admission. All of them 
were Caucasian, inhabitants of North-Eastern Poland. 
Early-deceased individuals were excluded from the study, 
because in their case genetic testing would have no poten-
tial role to play in clinical decision making. No other exclu-
sion criteria were implemented. Coronary angiography 
was performed within 12 h from symptoms onset in all 
patients. STEMI was diagnosed based on a rise in troponin 
I concentrations or creatine kinase–MB fraction activity 
accompanied by chest pain history and new ECG abnor-
malities (lasting >20 min ST-segment elevation or left bun-
dle branch block). In the analysis we included data from 
patients’ history, physical examination on admission, rou-
tine laboratory tests, echocardiography, results of coronary 
angiography and invasive treatment. Modification of diet in 
renal disease (MDRD) formula was used to estimate cre-
atinine clearance (eGFR) [14]. General risk assessment of 
each patient was performed with the Grace risk score, as 
previously described [15]. Pharmacological treatment was 
consistent with contemporary guidelines.
The control group included 222 adult men and 221 adult 
women, whose genetic material was collected for pater-
nity testing. Their clinical characteristics were not avail-
able. However, we assumed that selection of subjects for 
paternity testing was random from a clinical point of view. 
Therefore, such a group should be highly representative for 
our region in terms of genetic background.
Laboratory procedures
Laboratory procedures were described previously [16]. 
Blood samples were collected in EDTA tubes, treated with 
commercial DNA extraction kit (Blood Mini, A&A Bio-
technology) and stored at −20 degrees Celsius. The SNPs 
were assessed with a TaqMan SNP Genotyping Assay on 
the ABI 7500 real time PCR platform (Applied Biosys-
tems), according to manufacturer’s instructions. Ten per-
cent of samples were genotyped in duplicates.
End-point
Five-year all-cause mortality was the analyzed end-point. 
Data concerning deaths and dates of deaths were retrieved 
from the local population registry run by a Government 
Office.
Statistical analysis
STATISTICA 9.0 software was used for statistical analy-
sis. After testing for distribution with Shapiro–Wilk test, 
clinical parameters were compared between the genotypes 
with χ2 or Kruskal–Wallis tests, as appropriate. Survival 
was compared with log-rank test. Univariate and multivari-
ate analyses for 5-year survival were performed with Cox 
proportional hazards model. Based on analysis of survival 
curves and mortality rates, a recessive model of penetrance 
was assumed. Two-sided p value <0.05 was considered sta-
tistically significant. The biostatistical parameters were cal-
culated using ARLEQUIN v.3.0 software.
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Ethics statement
The study protocol was approved by the Ethics Committee 
of the Medical University of Bialystok. The study was per-
formed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki. Informed written con-
sent was obtained from all the subjects prior to their inclu-
sion in the study.
Results
Characteristics of the study group and genotyping results
A total of 652 patients were included in our registry. Nine 
patients were lost to follow-up (1.4 %) and in nine cases 
genotypes could not be determined due to poor sample 
quality. For all samples genotyped in duplicate consistent 
results were obtained. The final study group comprised 634 
patients (mean age 62.3 ± 11.85 years; 25.2 % of women, 
n = 160; PCI successful in 92.3 %, n = 585).
Genotyping results for both SNPs are presented in 
Table 1. No significant deviations from the Hardy–Wein-
berg equilibrium were found in the populations analyzed. 
There was only weak linkage disequilibrium between 
the rs662 and rs854560 polymorphisms, (LD = 0.0149, 
D` = 0.08, r2 = 0.0052, p = 0.01). The specific allele fre-
quencies differ between previous reports: however, our 
genetic distribution was comparable to European data-
bases (1, 3, 9). There was no significant difference between 
the study and control groups in haplotype distributions 
(p > 0.05, χ2 test).
Table 1  Percentages of specific 
genotypes and associated 
mortality rates. The difference 
between the study and control 
groups was not statistically 
significant (p > 0.05, χ2 test)
a Reports are ambiguous
Polymorphism (risk allele) rs662 (A?a) rs854560 (A)
Genotype AA AG GG AA AT TT
Study group (n = 634)
 Percentage (n) 52.4 (332) 40.7 (258) 6.9 (44) 46.7 (296) 42.4 (269) 10.9 (69)
 5-year mortality (n) 15.4 (51) 18.6 (48) 11.4 (5) 17.2 (51) 16.4 (44) 13.0 (9)
Control group (n = 443)
 Percentage (n) 54.8 (243) 39.7 (176) 5.4 (24) 45.4 (201) 45.1 (200) 9.5 (42)
Table 2  Baseline characteristics of the study group based on rs662 genotype
Mean values with standard deviations are given, unless otherwise specified. χ2 and Kruskal–Wallis tests were used to compare the three geno-
types. eGFR-estimated glomerular filtration rate









Age (years) 62.3 (11.8) 61.4 (11.7) 63.1 (12.0) 64.1 (11.8) 0.11
Female gender (%) 25.2 (n = 160) 25.6 (n = 88) 24.4 (n = 63) 20.5 (n = 9) 0.63
Hypertension (%) 54.7 (n = 347) 54.8 (n = 182) 55.4 (n = 143) 50 (n = 22) 0.79
Type 2 diabetes (%) 22.1 (n = 140) 22 (n = 73) 20.5 (n = 53) 31.8 (n = 14) 0.24
Hypercholesterolaemia (%) 54.4 (n = 345) 53.9 (n = 179) 53.5 (n = 138) 63.6 (n = 28) 0.44
Previous myocardial infarction (%) 11.2 (n = 71) 11.1 (n = 37) 11.6 (n = 30) 9.1 (n = 4) 0.88
Systolic blood pressure (mmHg) 138.6 (28.4) 138.7 (28.8) 137.8 (27.1) 142.2 (32.2) 0.91
Heart rate (beats/min) 75.8 (17.8) 75.2 (16.9) 76.3 (18.8) 76.9 (18.0) 0.94
Killip class III or IV (%) 6.5 (n = 41) 6.9 (n = 23) 5.8 (n = 15) 7.5 (n = 3) 0.85
ST-elevation in anterior leads 39.4 (n = 250) 39.5 (n = 131) 38.7 (n = 100) 43.2 (n = 19) 0.85
TIMI flow grade 3 after procedure 92.3 (n = 585) 93.4 (n = 310) 89.5 (n = 231) 100 (n = 44) 0.03
Stent implantation (%) 77 (n = 488) 80.7 (n = 268) 71.3 (n = 184) 81.8 (n = 36) 0.019
eGFR (ml/min/1.73 m2) 79.5 (23.2) 80.7 (24.1) 78.9 (22.4) 73.9 (19.5) 0.18
Total cholesterol (mg/dl) 195.7 (42.4) 195.3 (43.7) 195.6 (41.6) 198.5 (37.4) 0.78
HDL cholesterol (mg/dl) 43.7 (13.2) 43.6 (14) 43.6 (12) 45.3 (14.3) 0.44
LDL cholesterol (mg/dl) 128.0 (37.6) 127.9 (38.4) 127.5 (37.8) 132.1 (30.2) 0.58
Triglycerides (mg/dl) 125.2 (70) 123.7 (66.8) 128.1 (72.9) 120 (77.4) 0.8
Ejection fraction (%) 45.8 (9.5) 45.7 (9.4) 46.3 (9.5) 44.0 (10.6) 0.32
Grace risk score 149.8 (35.2) 147.1 (34.0) 152.3 (36.2) 154.6 (37.7) 0.17
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Tables 2 and 3 show clinical characteristics of the study 
group based on the rs662 and rs854560 genotypes, respec-
tively. There was a significant difference between rs662 
genotypes in the percentages of implanted stents and suc-
cessful angioplasties.
Survival analysis
During 5-year follow-up, 104 patients died (16.4 %). We 
observed no association between either genotype and sur-
vival. Figure 1 shows Kaplan–Meier surviving curves for 
specific genotypes of rs662 and rs854560 polymorphisms 
and 5-year mortality (p = 0.4 and p = 0.73, log-rank test). 
However, in a subgroup of patients with eGFR below 
median value (78.6 ml/min/1.73 m2, n = 317) the rs854560 
AA homozygotes had a significantly lower probability of 
survival compared to other genotypes (Fig. 2, p = 0.047, 
log-rank test). There died 38 out of 158 AA homozy-
gotes (24 %) and 24 out of 159 T-allele carriers (15.1 %, 
p = 0.044, χ2 test). In the case of the rs662 SNP there was 
no influence on survival depending on eGFR (data not 
shown). 
Table 4 presents parameters associated with 5-year sur-
vival in a subgroup of patients with eGFR below median 
value (univariate and multivariate analysis- Cox propor-
tional hazard model). The rs854560 AA genotype was one 
of the variables associated significantly with adverse 5-year 
survival (OR = 1.66, 95 % CI 1.0007–2.78, p = 0.049).
Discussion
Our study showed worse 5-year survival of the AA 
homozygotes of the rs854560 polymorphism, but only in a 
subgroup of patients with eGFR below median value. This 
phenomenon may be explained by decreased PON1 activity 
in the AA homozygotes of rs854560 SNP [7]. This results 
in the diminished antioxidant activity of HDL cholesterol, 
an increase in oxidative stress and endothelial dysfunction 
[6, 17], including decreased NO production [6].
Impaired renal function is associated with poor long-
term outcome of patients with myocardial infarction [18–
20]. One of the underlying mechanisms could be decreased 
HDL antioxidant activity [4], which would additionally 
augment the effect of rs854560 AA homozygosity and may 
trigger its phenotypic effect in terms of survival.
This observation was not confirmed for the rs662 geno-
type; however, the two investigated polymorphisms are 
in weak linkage disequilibrium. We also did not replicate 
associations between PON1 polymorphisms and either 
myocardial infarction or lipid profile. In general, this study 
was not designed for this purpose: however, the lack of 
Table 3  Baseline characteristics of the study group based on rs854560 genotype
Mean values with standard deviations are given, unless otherwise specified. χ2 and Kruskal–Wallis tests were used to compare the genotypes. 
eGFR-estimated glomerular filtration rate









Age (years) 62.3 (11.8) 62.7 (11.4) 62.3 (11.8) 60.5 (13.6) 0.54
Female gender (%) 25.2 (n = 160) 21.6 (n = 64) 26.8 (n = 72) 34.8 (n = 24) 0.054
Hypertension (%) 54.7 (n = 347) 51.7 (n = 153) 58 (n = 156) 55.1 (n = 38) 0.32
Type 2 diabetes (%) 22.1 (n = 140) 22.3 (n = 66) 21.2 (n = 57) 24.6 (n = 17) 0.82
Hypercholesterolaemia (%) 54.4 (n = 345) 55.4 (n = 164) 52.4 (n = 141) 58 (n = 40) 0.63
Previous myocardial infarction (%) 11.2 (n = 71) 11.1 (n = 33) 12.3 (n = 33) 7.2 (n = 5) 0.49
Systolic blood pressure (mmHg) 138.6 (28.4) 137.7 (27.4) 138.8 (30.2) 141.4 (25.3) 0.75
Heart rate (beats/min) 75.8 (17.8) 75.4 (18.8) 76.7 (17.2) 74.1 (15.6) 0.42
Killip class III or IV (%) 6.5 (n = 41) 3.7 (n = 22) 5.9 (n = 16) 4.3 (n = 3) 0.58
ST-elevation in anterior leads 39.4 (n = 250) 38.9 (n = 115) 40.1 (n = 108) 39 (n = 27) 0.95
TIMI flow grade 3 after procedure 92.3 (n = 585) 91.9 (n = 272) 91.8 (n = 247) 95.6 (n = 66) 0.53
Stent implantation (%) 77 (n = 488) 76.7 (n = 227) 76.6 (n = 206) 79.7 (n = 55) 0.84
eGFR (ml/min/1.73 m2) 79.5 (23.2) 78.6 (23.2) 80.8 (23.8) 77.8 (20.2) 0.39
Total cholesterol (mg/dl) 195.7 (42.4) 197.3 (42.5) 194.1 (42.2) 195.0 (43.1) 0.81
HDL cholesterol (mg/dl) 43.7 (13.2) 44.4 (14.7) 43.6 (11.8) 41.3 (10.8) 0.31
LDL cholesterol (mg/dl) 128.0 (37.6) 130.3 (38.4) 125.4 (37.1) 128.7 (36.0) 0.46
Triglycerides (mg/dl) 125.2 (70) 127.3 (73.5) 123.3 (64.4) 124 (76.4) 0.92
Ejection fraction (%) 45.8 (9.5) 44.9 (9.4) 46.5 (9.6) 46.9 (9.4) 0.09
Grace risk score 149.8 (35.2) 152.1 (38.4) 148.6 (32.7) 144.3 (30.1) 0.38
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such a link in a population of 634 patients undermines the 
clinical significance of this association.
Previous surveys concerning the investigated SNPs 
and coronary artery disease gave ambiguous results [3, 
10–13]. Generally, in the case of rs662 polymorphism, 
an AA genotype associated with lower PON1 activity is 
considered as high-risk [3]. However, it has been reported 
that PON1 activity in AA homozygotes decreases with 
advancing age when compared with other genotypes [3]. 
It is noteworthy that those authors showing G allele as a 
high-risk, reported the association with myocardial infarc-
tion only in relatively early-onset cases: <50 years [12] 
or <60 years [11]. Genotype-phenotype correlation might 
differ between populations due to multiform interactions 
based on genetic background and other clinical features. 
Therefore genetic studies should be validated in specific 
populations.
The GG genotype of the rs662 SNP was previously 
reported to be associated with a favorable lipid profile in 
the general population (lower total cholesterol, LDL frac-
tion, triglycerides and apolipoprotein B levels, higher 
HDL cholesterol level) [8]. This result was not replicated 
in our study group of patients with myocardial infarction. 
In general, in studies enrolling patients with coronary 
artery disease, cholesterol status is strongly influenced 
by statin treatment. Such patients are not an appropriate 
Fig. 1  a Kaplan–Meier surviv-
ing curves for specific geno-
types of rs662 polymorphism 
and 5-year mortality (p = 0.4, 
log-rank test). b Kaplan–Meier 
surviving curves for specific 
genotypes of rs854560 poly-
morphism and 5-year mortality 
(p = 0.73, log-rank test)
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group for revision of the influence of genetic factors on 
lipids. Interestingly, we observed in our study the so-
called “cholesterol paradox”. Lower total cholesterol 
levels were associated with an adverse outcome. This 
phenomenon has previously been reported in some stud-
ies including patients with myocardial infarction [15, 16, 
21–24]. In our case, this finding could have potentially 
increased the favorable effect of the GG genotype on sur-
vival, if such was observed.
The next parameter that potentially influences survival 
is oxidative stress. It has been shown that the AA geno-
type is associated with the highest oxidative stress mark-
ers levels and subsequent all-cause mortality in a group 
of patients undergoing coronary angiography [25]. On the 
Fig. 2  Subgroup of patients 
with eGFR below median 
value. Kaplan-Meier surviving 
curves for rs854560 polymor-
phism and 5-year mortality. AA 
homozygotes had significantly 
lower probability of survival 
compared to other genotypes 
(p = 0.047, log-rank test)
Table 4  A univariate analysis 
for 5-year mortality in a 
subgroup of patients with eGFR 
below median value. For all 
parameters baseline values are 
shown
Variable Odds ratio (95 % CI) p
Univariate analysis
Age (years) 1.05 (1.02–1.08) 0.0002
Type 2 diabetes 2.0 (1.2–3.3) 0.009
Arterial hypertension 1.5 (0.84–2.5) 0.17
Systolic blood pressure (mmHg) 0.99 (0.98–0.999) 0.04
Heart rate (beats/min) 1.0 (0.98–1.01) 0.99
Killip class 1.9 (1.5–2.4) <0.0001
Total cholesterol (mg/dl) 0.99 (0.98–0.997) 0.008
HDL cholesterol (mg/dl) 0.99 (0.97–1.01) 0.37
LDL cholesterol (mg/dl) 0.99 (0.98–1.0) 0.056
Triglycerides (mg/dl) 0.996 (0.992–1.001) 0.17
Ejection fraction (%) 0.95 (0.93–0.97) 0.0001
TIMI 3 flow after invasive procedure 0.42 (0.22–0.86) 0.01
Grace risk score 1.02 (1.012–1.02) <0.0001
Rs854560 AA genotype 1.67 (1.0–2.8) 0.049
Rs662 AA genotype 0.88 (0.53–1.45) 0.63
Multivariate analysis χ2 = 40.9
Age (years) 1.045 (1.017–1.07) 0.0012
Killip class 1.8 (1.4–2.3) <0.0001
Type 2 diabetes 1.79 (1.07–3.0) 0.025
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other hand, tumor necrosis factor alpha−one of the sys-
temic inflammation markers− was shown to be signifi-
cantly higher in GG homozygotes [26].
PON1 has an impact on clopidogrel absorption and acti-
vation [27]. This phenomenon was not confirmed in vivo 
and has no clinical impact. All these findings show com-
plexity of the link between PON1 SNPs and cardiovascu-
lar disease or subsequent mortality. They also may explain 
hypothetically ambiguous results of previous studies.
Limitations of the study
We are fully aware of the limitations of the study. The 
analysis was performed retrospectively (however the data 
was collected in a prospective manner). Next, the number 
of patients included is relatively small. Large study groups 
enable finding associations of very small effect sizes, but 
these frequently have no real clinical impact. Investigating 
large effects are more promising for clinical practice, as 
more cost-effective.
Conclusions
The AA genotype of the rs854560 SNPs of the PON1 gene 
was associated with increased 5-year mortality of patients 
with STEMI treated invasively, but only under condition of 
eGFR decreased below median value.
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